Role of a Janus kinase 2-dependent signaling pathway in platelet activation

Wan-Jung Lu, Kao Chang Lin, Shih Yi Huang, Philip Aloysius Thomas, Yu Hua Wu, Hsu Chu Wu, Kuan Hung Lin, Joen Rong Sheu

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction Janus kinases (JAKs) are intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals through a pathway mediated by JAK and the signal transducer and activator of transcription (STAT) proteins. The JAK-STAT pathway is involved in immune response, inflammation, and tumorigenesis. Platelets are anuclear blood cells that play a central role in hemostasis. Methods The aggregometry, immunoblotting, and platelet functional analysis used in this study. Results We found that the JAK2 inhibitor AG490 (25 and 50 μM) attenuated collagen-induced platelet aggregation and calcium mobilization in a concentration-dependent manner. In the presence of AG490, the phosphorylation of PLCγ2, protein kinase C (PKC), Akt or JNK in collagen-activated aggregation of human platelets was also inhibited. In addition, we found that various inhibitors, such as the PLCγ2 inhibitor U73122, the PKC inhibitor Ro318220, the phospoinositide 3-kinase inhibitor LY294002, the p38 mitogen-activated protein kinase inhibitor SB203580, the ERK inhibitor PD98059, and the JNK inhibitor SP600125, had no effects on collagen-induced JAK2 activity. However, U73122, Ro318220 and SP600125 significantly diminished collagen-induced STAT3 phosphorylation. These findings suggest that PLCγ2-PKC and JNK are involved in JAK2-STAT3 signaling in collagen-activated platelets. Conclusion Our results demonstrate that the JAK2-STAT3 pathway is involved in collagen-induced platelet activation through the activation of JAK2-JNK/PKC-STAT3 signaling. The inhibition of JAK2 may represent a potential therapeutic strategy for the preventing or treating thromboembolic disorders.

Original languageEnglish
Pages (from-to)1088-1096
Number of pages9
JournalThrombosis Research
Volume133
Issue number6
DOIs
Publication statusPublished - 2014

Fingerprint

Janus Kinase 2
Platelet Activation
Collagen
Janus Kinases
Protein Kinase C
Blood Platelets
Protein Kinase Inhibitors
Platelet Aggregation
Phosphorylation
STAT Transcription Factors
MAP Kinase Kinase 4
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one
Protein C Inhibitor
p38 Mitogen-Activated Protein Kinases
Hemostasis
Transducers
Immunoblotting
Protein-Tyrosine Kinases
Blood Cells
Carcinogenesis

Keywords

  • AG490
  • JAK2
  • JNK
  • PKC
  • Platelet activation

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Cite this

Role of a Janus kinase 2-dependent signaling pathway in platelet activation. / Lu, Wan-Jung; Lin, Kao Chang; Huang, Shih Yi; Thomas, Philip Aloysius; Wu, Yu Hua; Wu, Hsu Chu; Lin, Kuan Hung; Sheu, Joen Rong.

In: Thrombosis Research, Vol. 133, No. 6, 2014, p. 1088-1096.

Research output: Contribution to journalArticle

Lu, Wan-Jung ; Lin, Kao Chang ; Huang, Shih Yi ; Thomas, Philip Aloysius ; Wu, Yu Hua ; Wu, Hsu Chu ; Lin, Kuan Hung ; Sheu, Joen Rong. / Role of a Janus kinase 2-dependent signaling pathway in platelet activation. In: Thrombosis Research. 2014 ; Vol. 133, No. 6. pp. 1088-1096.
@article{d05600ecd824409798406b343c2c9532,
title = "Role of a Janus kinase 2-dependent signaling pathway in platelet activation",
abstract = "Introduction Janus kinases (JAKs) are intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals through a pathway mediated by JAK and the signal transducer and activator of transcription (STAT) proteins. The JAK-STAT pathway is involved in immune response, inflammation, and tumorigenesis. Platelets are anuclear blood cells that play a central role in hemostasis. Methods The aggregometry, immunoblotting, and platelet functional analysis used in this study. Results We found that the JAK2 inhibitor AG490 (25 and 50 μM) attenuated collagen-induced platelet aggregation and calcium mobilization in a concentration-dependent manner. In the presence of AG490, the phosphorylation of PLCγ2, protein kinase C (PKC), Akt or JNK in collagen-activated aggregation of human platelets was also inhibited. In addition, we found that various inhibitors, such as the PLCγ2 inhibitor U73122, the PKC inhibitor Ro318220, the phospoinositide 3-kinase inhibitor LY294002, the p38 mitogen-activated protein kinase inhibitor SB203580, the ERK inhibitor PD98059, and the JNK inhibitor SP600125, had no effects on collagen-induced JAK2 activity. However, U73122, Ro318220 and SP600125 significantly diminished collagen-induced STAT3 phosphorylation. These findings suggest that PLCγ2-PKC and JNK are involved in JAK2-STAT3 signaling in collagen-activated platelets. Conclusion Our results demonstrate that the JAK2-STAT3 pathway is involved in collagen-induced platelet activation through the activation of JAK2-JNK/PKC-STAT3 signaling. The inhibition of JAK2 may represent a potential therapeutic strategy for the preventing or treating thromboembolic disorders.",
keywords = "AG490, JAK2, JNK, PKC, Platelet activation",
author = "Wan-Jung Lu and Lin, {Kao Chang} and Huang, {Shih Yi} and Thomas, {Philip Aloysius} and Wu, {Yu Hua} and Wu, {Hsu Chu} and Lin, {Kuan Hung} and Sheu, {Joen Rong}",
year = "2014",
doi = "10.1016/j.thromres.2014.03.042",
language = "English",
volume = "133",
pages = "1088--1096",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",
number = "6",

}

TY - JOUR

T1 - Role of a Janus kinase 2-dependent signaling pathway in platelet activation

AU - Lu, Wan-Jung

AU - Lin, Kao Chang

AU - Huang, Shih Yi

AU - Thomas, Philip Aloysius

AU - Wu, Yu Hua

AU - Wu, Hsu Chu

AU - Lin, Kuan Hung

AU - Sheu, Joen Rong

PY - 2014

Y1 - 2014

N2 - Introduction Janus kinases (JAKs) are intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals through a pathway mediated by JAK and the signal transducer and activator of transcription (STAT) proteins. The JAK-STAT pathway is involved in immune response, inflammation, and tumorigenesis. Platelets are anuclear blood cells that play a central role in hemostasis. Methods The aggregometry, immunoblotting, and platelet functional analysis used in this study. Results We found that the JAK2 inhibitor AG490 (25 and 50 μM) attenuated collagen-induced platelet aggregation and calcium mobilization in a concentration-dependent manner. In the presence of AG490, the phosphorylation of PLCγ2, protein kinase C (PKC), Akt or JNK in collagen-activated aggregation of human platelets was also inhibited. In addition, we found that various inhibitors, such as the PLCγ2 inhibitor U73122, the PKC inhibitor Ro318220, the phospoinositide 3-kinase inhibitor LY294002, the p38 mitogen-activated protein kinase inhibitor SB203580, the ERK inhibitor PD98059, and the JNK inhibitor SP600125, had no effects on collagen-induced JAK2 activity. However, U73122, Ro318220 and SP600125 significantly diminished collagen-induced STAT3 phosphorylation. These findings suggest that PLCγ2-PKC and JNK are involved in JAK2-STAT3 signaling in collagen-activated platelets. Conclusion Our results demonstrate that the JAK2-STAT3 pathway is involved in collagen-induced platelet activation through the activation of JAK2-JNK/PKC-STAT3 signaling. The inhibition of JAK2 may represent a potential therapeutic strategy for the preventing or treating thromboembolic disorders.

AB - Introduction Janus kinases (JAKs) are intracellular non-receptor tyrosine kinases that transduce cytokine-mediated signals through a pathway mediated by JAK and the signal transducer and activator of transcription (STAT) proteins. The JAK-STAT pathway is involved in immune response, inflammation, and tumorigenesis. Platelets are anuclear blood cells that play a central role in hemostasis. Methods The aggregometry, immunoblotting, and platelet functional analysis used in this study. Results We found that the JAK2 inhibitor AG490 (25 and 50 μM) attenuated collagen-induced platelet aggregation and calcium mobilization in a concentration-dependent manner. In the presence of AG490, the phosphorylation of PLCγ2, protein kinase C (PKC), Akt or JNK in collagen-activated aggregation of human platelets was also inhibited. In addition, we found that various inhibitors, such as the PLCγ2 inhibitor U73122, the PKC inhibitor Ro318220, the phospoinositide 3-kinase inhibitor LY294002, the p38 mitogen-activated protein kinase inhibitor SB203580, the ERK inhibitor PD98059, and the JNK inhibitor SP600125, had no effects on collagen-induced JAK2 activity. However, U73122, Ro318220 and SP600125 significantly diminished collagen-induced STAT3 phosphorylation. These findings suggest that PLCγ2-PKC and JNK are involved in JAK2-STAT3 signaling in collagen-activated platelets. Conclusion Our results demonstrate that the JAK2-STAT3 pathway is involved in collagen-induced platelet activation through the activation of JAK2-JNK/PKC-STAT3 signaling. The inhibition of JAK2 may represent a potential therapeutic strategy for the preventing or treating thromboembolic disorders.

KW - AG490

KW - JAK2

KW - JNK

KW - PKC

KW - Platelet activation

UR - http://www.scopus.com/inward/record.url?scp=84900518234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900518234&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2014.03.042

DO - 10.1016/j.thromres.2014.03.042

M3 - Article

C2 - 24731555

AN - SCOPUS:84900518234

VL - 133

SP - 1088

EP - 1096

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

IS - 6

ER -